Plasminogen activator inhibitor-1 in kidney pathology (Review)
- Authors:
- Sylwia Małgorzewicz
- Ewa Skrzypczak-Jankun
- Jerzy Jankun
-
Affiliations: Department of Clinical Nutrition, Medical University of Gdańsk, Gdańsk 80-211, Poland, Urology Research Center, Department of Urology, College of Medicine, University of Toledo, Toledo, OH 43614, USA - Published online on: January 10, 2013 https://doi.org/10.3892/ijmm.2013.1234
- Pages: 503-510
This article is mentioned in:
Abstract
Buduneli N, Buduneli E, Ciotanar S, Atilla G, Lappin D and Kinane D: Plasminogen activators and plasminogen activator inhibitors in gingival crevicular fluid of cyclosporin A-treated patients. J Clin Periodontol. 31:556–561. 2004. View Article : Google Scholar : PubMed/NCBI | |
Chorostowska-Wynimko J, Swiercz R, Skrzypczak-Jankun E, Wojtowicz A, Selman SH and Jankun J: A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis. Mol Cancer Ther. 2:19–28. 2003. View Article : Google Scholar : PubMed/NCBI | |
Chow KM, Szeto CC, Szeto CY, Poon P, Lai FM and Li PK: Plasminogen activator inhibitor-1 polymorphism is associated with progressive renal dysfunction after acute rejection in renal transplant recipients. Transplantation. 74:1791–1794. 2002. View Article : Google Scholar : PubMed/NCBI | |
Fay WP, Parker AC, Condrey LR and Shapiro AD: Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. Blood. 90:204–208. 1997.PubMed/NCBI | |
Jankun J, Aleem AM, Struniawski R, Lysiak-Szydlowska W, Selman SH and Skrzypczak-Jankun E: Accelerated thrombus lysis in the blood of plasminogen activator inhibitor deficient mice is inhibited by PAI-1 with a very long half-life. Pharmacol Rep. 61:673–680. 2009. View Article : Google Scholar : PubMed/NCBI | |
Zhu Y, Carmeliet P and Fay WP: Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation. 99:3050–3055. 1999. View Article : Google Scholar : PubMed/NCBI | |
Lopes C, Dina C, Durand E and Froguel P: PAI-1 polymorphisms modulate phenotypes associated with the metabolic syndrome in obese and diabetic Caucasian population. Diabetologia. 46:1284–1290. 2003. View Article : Google Scholar : PubMed/NCBI | |
Babu MS, Prabha TS, Kaul S, et al: Association of genetic variants of fibrinolytic system with stroke and stroke subtypes. Gene. 495:76–80. 2012. View Article : Google Scholar : PubMed/NCBI | |
Jood K, Ladenvall P, Tjarnlund-Wolf A, et al: Fibrinolytic gene polymorphism and ischemic stroke. Stroke. 36:2077–2081. 2005. View Article : Google Scholar : PubMed/NCBI | |
Wiklund PG, Nilsson L, Ardnor SN, et al: Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: replicated findings in two nested case-control studies based on independent cohorts. Stroke. 36:1661–1665. 2005. View Article : Google Scholar : PubMed/NCBI | |
Ringelstein M, Jung A, Berger K, et al: Promotor polymorphisms of plasminogen activator inhibitor-1 and other thrombophilic genotypes in cerebral venous thrombosis: a case-control study in adults. J Neurol. Apr 12–2012.(Epub ahead of print). | |
Jankun J, Aleem AM, Selman SH, Basrur V and Skrzypczak-Jankun E: VLHL plasminogen activator inhibitor spontaneously reactivates from the latent to active form. Int J Mol Med. 23:57–63. 2009.PubMed/NCBI | |
Jankun J and Skrzypczak-Jankun E: Yin and yang of the plasminogen activator inhibitor. Pol Arch Med Wewn. 119:410–417. 2009.PubMed/NCBI | |
Lim JH, Stirling B, Derry J, et al: Tumor suppressor CYLD regulates acute lung injury in lethal Streptococcus pneumoniae infections. Immunity. 27:349–360. 2007. View Article : Google Scholar : PubMed/NCBI | |
Eddy AA and Fogo AB: Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol. 17:2999–3012. 2006. View Article : Google Scholar : PubMed/NCBI | |
Lottermoser K, Petras S, Poge U, et al: The fibrinolytic system in chronic renal failure. Eur J Med Res. 6:372–376. 2001.PubMed/NCBI | |
Rerolle JP, Munteanu E, Drouet M, et al: PAI-1 donor polymorphism influences long-term kidney graft survival. Nephrol Dial Transplant. 23:3325–3332. 2008. View Article : Google Scholar : PubMed/NCBI | |
Wang Y, Pratt JR, Hartley B, Evans B, Zhang L and Sacks SH: Expression of tissue type plasminogen activator and type 1 plasminogen activator inhibitor, and persistent fibrin deposition in chronic renal allograft failure. Kidney Int. 52:371–377. 1997. View Article : Google Scholar : PubMed/NCBI | |
Bedke J, Kiss E, Schaefer L, et al: Beneficial effects of CCR1 blockade on the progression of chronic renal allograft damage. Am J Transplant. 7:527–537. 2007. View Article : Google Scholar : PubMed/NCBI | |
Delarue F, Hertig A, Alberti C, et al: Prognostic value of plasminogen activator inhibitor type 1 mRNA in microdissected glomeruli from transplanted kidneys. Transplantation. 72:1256–1261. 2001. View Article : Google Scholar : PubMed/NCBI | |
Chang HR, Yang SF, Lian JD, et al: Prediction of chronic allograft damage index of renal allografts using serum level of plasminogen activator inhibitor-1. Clin Transplant. 23:206–212. 2009. View Article : Google Scholar : PubMed/NCBI | |
Reis K, Arinsoy T, Derici U, et al: Angiotensinogen and plasminogen activator inhibitor-1 gene polymorphism in relation to chronic allograft dysfunction. Clin Transplant. 19:10–14. 2005. View Article : Google Scholar : PubMed/NCBI | |
Pontrelli P, Rossini M, Infante B, et al: Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy. Transplantation. 85:125–134. 2008. View Article : Google Scholar : PubMed/NCBI | |
Ishikawa A, Ohta N, Ozono S, Kawabe K and Kitamura T: Inhibition of plasminogen activator inhibitor-1 by angiotensin II receptor blockers on cyclosporine-treated renal allograft recipients. Transplant Proc. 37:994–996. 2005. View Article : Google Scholar : PubMed/NCBI | |
Ishikawa A, Tanaka M, Ohta N, Ozono S and Kitamura T: Prevention of interstitial fibrosis of renal allograft by angiotensin II blockade. Transplant Proc. 38:3498–3501. 2006. View Article : Google Scholar : PubMed/NCBI | |
Lahlou A, Peraldi MN, Thervet E, et al: Chronic graft dysfunction in renal transplant patients: potential role of plasminogen activator inhibitor type 1. Transplantation. 73:1290–1295. 2002. View Article : Google Scholar : PubMed/NCBI | |
Revelo MP, Federspiel C, Helderman H and Fogo AB: Chronic allograft nephropathy: expression and localization of PAI-1 and PPAR-gamma. Nephrol Dial Transplant. 20:2812–2819. 2005. View Article : Google Scholar : PubMed/NCBI | |
Grandaliano G, Di Paolo S, Monno R, et al: Protease-activated receptor 1 and plasminogen activator inhibitor 1 expression in chronic allograft nephropathy: the role of coagulation and fibrinolysis in renal graft fibrosis. Transplantation. 72:1437–1443. 2001. View Article : Google Scholar : PubMed/NCBI | |
Alessi MC, Bastelica D, Morange P, et al: Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes. 49:1374–1380. 2000. View Article : Google Scholar | |
Brown NJ: Therapeutic potential of plasminogen activator inhibitor-1 inhibitors. Ther Adv Cardiovasc Dis. 4:315–324. 2010. View Article : Google Scholar : PubMed/NCBI | |
Grant PJ: Diabetes mellitus as a prothrombotic condition. J Intern Med. 262:157–172. 2007. View Article : Google Scholar : PubMed/NCBI | |
Wang Y, Thompson EM, Whawell SA and Fleming KA: Expression and localization of plasminogen activator inhibitor 1 mRNA in transplant kidneys. J Pathol. 169:445–450. 1993. View Article : Google Scholar : PubMed/NCBI | |
Patrassi GM, Sartori MT, Rigotti P, et al: Reduced fibrinolytic potential one year after kidney transplantation. Relationship to long-term steroid treatment. Transplantation. 59:1416–1420. 1995.PubMed/NCBI | |
Jankun J, Skotnicka M, Lysiak-Szydlowska W, Al-Senaidy A and Skrzypczak-Jankun E: Diverse inhibition of plasminogen activator inhibitor type 1 by theaflavins of black tea. Int J Mol Med. 27:525–529. 2011. View Article : Google Scholar : PubMed/NCBI | |
Badawi A, Klip A, Haddad P, et al: Type 2 diabetes mellitus and inflammation: Prospects for biomarkers of risk and nutritional intervention. Diabetes Metab Syndr Obes. 3:173–186. 2010. View Article : Google Scholar : PubMed/NCBI | |
Birgel M, Gottschling-Zeller H, Rohrig K and Hauner H: Role of cytokines in the regulation of plasminogen activator inhibitor-1 expression and secretion in newly differentiated subcutaneous human adipocytes. Arterioscler Thromb Vasc Biol. 20:1682–1687. 2000. View Article : Google Scholar : PubMed/NCBI | |
Samad F and Loskutoff DJ: The fat mouse: a powerful genetic model to study elevated plasminogen activator inhibitor 1 in obesity/NIDDM. Thromb Haemost. 78:652–655. 1997.PubMed/NCBI | |
Meshkani R and Adeli K: Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clin Biochem. 42:1331–1346. 2009. View Article : Google Scholar : PubMed/NCBI | |
Chen LL, Zhang JY and Wang BP: Renoprotective effects of fenofibrate in diabetic rats are achieved by suppressing kidney plasminogen activator inhibitor-1. Vascul Pharmacol. 44:309–315. 2006. View Article : Google Scholar : PubMed/NCBI | |
Hagiwara H, Kaizu K, Uriu K, et al: Expression of type-1 plasminogen activator inhibitor in the kidney of diabetic rat models. Thromb Res. 111:301–309. 2003. View Article : Google Scholar : PubMed/NCBI | |
Lee HB and Ha H: Plasminogen activator inhibitor-1 and diabetic nephropathy. Nephrology (Carlton). 10(Suppl): S11–S13. 2005. View Article : Google Scholar : PubMed/NCBI | |
Lassila M, Fukami K, Jandeleit-Dahm K, et al: Plasminogen activator inhibitor-1 production is pathogenetic in experimental murine diabetic renal disease. Diabetologia. 50:1315–1326. 2007. View Article : Google Scholar : PubMed/NCBI | |
Miyata T and van Ypersele de Strihou C: Translation of basic science into clinical medicine: novel targets for diabetic nephropathy. Nephrol Dial Transplant. 24:1373–1377. 2009. View Article : Google Scholar : PubMed/NCBI | |
Nicholas SB, Aguiniga E, Ren Y, et al: Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kidney Int. 67:1297–1307. 2005. View Article : Google Scholar : PubMed/NCBI | |
Huang Y, Border WA, Lawrence DA and Noble NA: Mechanisms underlying the antifibrotic properties of noninhibitory PAI-1 (PAI-1R) in experimental nephritis. Am J Physiol Renal Physiol. 297:F1045–F1054. 2009. View Article : Google Scholar : PubMed/NCBI | |
Oh KS, Kim EY, Yoon M and Lee CM: Swim training improves leptin receptor deficiency-induced obesity and lipid disorder by activating uncoupling proteins. Exp Mol Med. 39:385–394. 2007. View Article : Google Scholar : PubMed/NCBI | |
Huang Y, Border WA, Yu L, Zhang J, Lawrence DA and Noble NA: A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy. J Am Soc Nephrol. 19:329–338. 2008. View Article : Google Scholar : PubMed/NCBI | |
Ho CH and Jap TS: Relationship of plasminogen activator inhibitor-1 with plasma insulin, glucose, triglyceride and cholesterol in Chinese patients with diabetes. Thromb Res. 69:271–277. 1993. View Article : Google Scholar : PubMed/NCBI | |
Festa A, Williams K, Tracy RP, Wagenknecht LE and Haffner SM: Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes. Circulation. 113:1753–1759. 2006. View Article : Google Scholar : PubMed/NCBI | |
Nagi DK, Tracy R and Pratley R: Relationship of hepatic and peripheral insulin resistance with plasminogen activator inhibitor-1 in Pima Indians. Metabolism. 45:1243–1247. 1996. View Article : Google Scholar : PubMed/NCBI | |
Collins SJ, Alexander SL, Lopez-Guisa JM, et al: Plasminogen activator inhibitor-1 deficiency has renal benefits but some adverse systemic consequences in diabetic mice. Nephron Exp Nephrol. 104:e23–e34. 2006. View Article : Google Scholar : PubMed/NCBI | |
Meigs JB, Dupuis J, Liu C, et al: PAI-1 Gene 4G/5G polymorphism and risk of type 2 diabetes in a population-based sample. Obesity (Silver Spring). 14:753–758. 2006. View Article : Google Scholar : PubMed/NCBI | |
Samarakoon R, Overstreet JM, Higgins SP and Higgins PJ: TGF-β1 → SMAD/p53/USF2 → PAI-1 transcriptional axis in ureteral obstruction-induced renal fibrosis. Cell Tissue Res. 347:117–128. 2012. | |
Stam F, van Guldener C, Schalkwijk CG, ter Wee PM, Donker AJ and Stehouwer CD: Impaired renal function is associated with markers of endothelial dysfunction and increased inflammatory activity. Nephrol Dial Transplant. 18:892–898. 2003. View Article : Google Scholar : PubMed/NCBI | |
Smyr KV, Shcherbak AV, Kozlovskaia LV, Sokolova IA, Bobkova IN and Podorolskaia LV: Significance of the markers of endothelial dysfunction and hemorheological disorders for assessing the activity and prognosis of chronic glomerulonephritis. Ter Arkh. 82:47–51. 2010.(In Russian). | |
Folsom AR, Delaney JA, Lutsey PL, et al: Associations of factor VIIIc, D-dimer, and plasmin-antiplasmin with incident cardiovascular disease and all-cause mortality. Am J Hematol. 84:349–353. 2009. View Article : Google Scholar : PubMed/NCBI | |
Dubin R, Cushman M, Folsom AR, et al: Kidney function and multiple hemostatic markers: cross sectional associations in the multi-ethnic study of atherosclerosis. BMC Nephrol. 12:32011. View Article : Google Scholar : PubMed/NCBI | |
Coresh J, Astor B and Sarnak MJ: Evidence for increased cardiovascular disease risk in patients with chronic kidney disease. Curr Opin Nephrol Hypertens. 13:73–81. 2004. View Article : Google Scholar : PubMed/NCBI | |
Hellenthal FA, Buurman WA, Wodzig WK and Schurink GW: Biomarkers of AAA progression. Part 1: extracellular matrix degeneration. Nat Rev Cardiol. 6:464–474. 2009. View Article : Google Scholar : PubMed/NCBI | |
Marney AM, Ma J, Luther JM, Ikizler TA and Brown NJ: Endogenous bradykinin contributes to increased plasminogen activator inhibitor 1 antigen following hemodialysis. J Am Soc Nephrol. 20:2246–2252. 2009. View Article : Google Scholar | |
Horl WH: Hemodialysis membranes: interleukins, biocompatibility, and middle molecules. J Am Soc Nephrol. 13(Suppl 1): S62–S71. 2002.PubMed/NCBI | |
Segarra A, Chacon P, Martinez-Eyarre C, et al: Circulating levels of plasminogen activator inhibitor type-1, tissue plasminogen activator, and thrombomodulin in hemodialysis patients: biochemical correlations and role as independent predictors of coronary artery stenosis. J Am Soc Nephrol. 12:1255–1263. 2001. | |
Arikan H, Koc M, Tuglular S, Ozener C and Akoglu E: Elevated plasma levels of PAI-1 predict cardiovascular events and cardiovascular mortality in prevalent peritoneal dialysis patients. Ren Fail. 31:438–445. 2009. View Article : Google Scholar | |
Nakamura Y, Tomura S, Tachibana K, Chida Y and Marumo F: Enhanced fibrinolytic activity during the course of hemodialysis. Clin Nephrol. 38:90–96. 1992.PubMed/NCBI | |
Kunz K, Petitjean P, Lisri M, et al: Cardiovascular morbidity and endothelial dysfunction in chronic haemodialysis patients: is homocyst(e)ine the missing link? Nephrol Dial Transplant. 14:1934–1942. 1999. View Article : Google Scholar : PubMed/NCBI | |
Stefoni S, Cianciolo G, Donati G, et al: Low TGF-beta1 serum levels are a risk factor for atherosclerosis disease in ESRD patients. Kidney Int. 61:324–335. 2002. View Article : Google Scholar : PubMed/NCBI | |
Kim KJ, Yang WS, Kim SB, Lee SK and Park JS: Fibrinogen and fibrinolytic activity in CAPD patients with atherosclerosis and its correlation with serum albumin. Perit Dial Int. 17:157–161. 1997.PubMed/NCBI | |
Gray RP, Mohamed-Ali V, Patterson DL and Yudkin JS: Determinants of plasminogen activator inhibitor-1 activity in survivors of myocardial infarction. Thromb Haemost. 73:261–267. 1995.PubMed/NCBI | |
Pawlak K, Mysliwiec M and Pawlak D: Haemostatic system, biochemical profiles, kynurenines and the prevalence of cardiovascular disease in peritoneally dialyzed patients. Thromb Res. 125:40–45. 2010. View Article : Google Scholar : PubMed/NCBI | |
Malyszko J, Malyszko JS, Brzosko S, Wolczynski S and Mysliwiec M: Adiponectin is related to CD146, a novel marker of endothelial cell activation/injury in chronic renal failure and peritoneally dialyzed patients. J Clin Endocrinol Metab. 89:4620–4627. 2004. View Article : Google Scholar : PubMed/NCBI | |
Maruyoshi H, Kojima S, Funahashi T, et al: Adiponectin is inversely related to plasminogen activator inhibitor type 1 in patients with stable exertional angina. Thromb Haemost. 91:1026–1030. 2004.PubMed/NCBI | |
Lin JJ, Singhal K, Parton L, Cascio C, Patlak CS and Stewart CL: Correlations between plasminogen activator inhibitor-1 and peritoneal transport in pediatric CCPD patients. Perit Dial Int. 15:246–251. 1995.PubMed/NCBI | |
Chang HR, Yang SF, Tsai JP, et al: Plasminogen activator inhibitor-1 5G/5G genotype is a protecting factor preventing posttransplant diabetes mellitus. Clin Chim Acta. 412:322–326. 2011. View Article : Google Scholar | |
Gao MJ, Liu M, Li B, Li ML, Bian LX and Yu GN: Protective effect of calcium dobesilate against early diabetic nephropathy of rat kidney. Yao Xue Xue Bao. 44:126–133. 2009.(In Chinese). | |
Qi W, Poronnik P, Young B, Jackson CJ, Field MJ and Pollock CA: Human cortical fibroblast responses to high glucose and hypoxia. Nephron Physiol. 96:121–129. 2004. View Article : Google Scholar : PubMed/NCBI | |
Czekay RP, Aertgeerts K, Curriden SA and Loskutoff DJ: Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol. 160:781–791. 2003. View Article : Google Scholar : PubMed/NCBI | |
Jankun J, Aleem AM, Specht Z, et al: PAI-1 induces cell detachment, downregulates nucleophosmin (B23) and fortilin (TCTP) in LnCAP prostate cancer cells. Int J Mol Med. 20:11–20. 2007.PubMed/NCBI | |
Guo B, Inoki K, Isono M, et al: MAPK/AP-1-dependent regulation of PAI-1 gene expression by TGF-beta in rat mesangial cells. Kidney Int. 68:972–984. 2005. View Article : Google Scholar : PubMed/NCBI | |
Huang W, Xu C, Kahng KW, Noble NA, Border WA and Huang Y: Aldosterone and TGF-beta1 synergistically increase PAI-1 and decrease matrix degradation in rat renal mesangial and fibroblast cells. Am J Physiol Renal Physiol. 294:F1287–F1295. 2008. View Article : Google Scholar : PubMed/NCBI | |
Ma J, Weisberg A, Griffin JP, Vaughan DE, Fogo AB and Brown NJ: Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury. Kidney Int. 69:1064–1072. 2006. View Article : Google Scholar : PubMed/NCBI | |
Ma LJ, Yang H, Gaspert A, et al: Transforming growth factor-beta-dependent and -independent pathways of induction of tubulointerstitial fibrosis in beta6(−/−) mice. Am J Pathol. 163:1261–1273. 2003.PubMed/NCBI | |
Song CY, Kim BC, Hong HK and Lee HS: TGF-beta type II receptor deficiency prevents renal injury via decrease in ERK activity in crescentic glomerulonephritis. Kidney Int. 71:882–888. 2007. View Article : Google Scholar : PubMed/NCBI | |
Tesch GH and Lim AK: Recent insights into diabetic renal injury from the db/db mouse model of type 2 diabetic nephropathy. Am J Physiol Renal Physiol. 300:F301–F310. 2011. View Article : Google Scholar : PubMed/NCBI | |
Choudhury D, Tuncel M and Levi M: Diabetic nephropathy - a multifaceted target of new therapies. Discov Med. 10:406–415. 2010.PubMed/NCBI | |
Guney I, Selcuk NY, Altintepe L, Atalay H, Basarali MK and Buyukbas S: Antifibrotic effects of aldosterone receptor blocker (spironolactone) in patients with chronic kidney disease. Ren Fail. 31:779–784. 2009. View Article : Google Scholar : PubMed/NCBI | |
Peters H, Border WA and Noble NA: Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade. Kidney Int. 54:1570–1580. 1998. View Article : Google Scholar : PubMed/NCBI | |
Yu L, Border WA, Anderson I, McCourt M, Huang Y and Noble NA: Combining TGF-beta inhibition and angiotensin II blockade results in enhanced antifibrotic effect. Kidney Int. 66:1774–1784. 2004. View Article : Google Scholar : PubMed/NCBI |